Antibodies to TNF Alpha

Abstract

Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNFα); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.

1 . An isolated antibody or antigen binding portion thereof capable of binding TNF-α wherein, either:
 (a) the V H  (variable heavy chain) antibody chain comprises CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 43, 44, and 45 respectively and wherein the V L  (variable light chain) antibody chain comprises CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 49, 50 and 51, respectively, excluding an isolated antibody or antigen binding portion thereof capable of binding TNF-α wherein the V H  antibody chain comprises CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 46, 47, and 48 respectively and wherein the V L  antibody chain comprises at least one of the V L  CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 52, 53 and 54, respectively; 
 (b) the V H  antibody chain comprises CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 43, 44, and 45 respectively and wherein the V L  antibody chain comprises CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 49, 50 and 51, respectively, and wherein the heavy chain V H  region has a G at position 30; 
 (c) the V H  antibody chain comprises a sequence selected from the group consisting of SEQ ID NO: 21, 22, 23, 24, 25 and 26, excluding sequences identified by SEQ ID NO: 40; 
 (d) the V H  antibody chain comprises the sequence identified by SEQ ID NO: 23; 
 (e) the V H  antibody chain comprises the sequence identified by SEQ ID NO: 24; 
 (f) V H  and V L  antibody chains comprise a sequence selected from the group consisting of SEQ ID NOs: 149, 265, 271, 291, 295, 303, 309, 313, 321, 359, 401, 402 and 453 and selected from the group consisting of SEQ ID NOs: 150, 266, 272, 292, 296, 304, 310, 314, 322, 360 and 454, respectively; or 
 (g) antibody heavy and light chains comprise a sequence selected from the group consisting of SEQ ID NOs: 147, 263, 269, 289, 293, 301, 307, 311, 319, 357, 373 and 399 and selected from the group consisting of SEQ ID NOs: 148, 264, 270, 290, 294, 302, 308, 312, 320, 358, 374 and 400, respectively. 
 
     
     
         2 . The isolated antibody or antigen binding portion thereof of  claim 1 , wherein the antibody is a bispecific antibody. 
     
     
         3 . The isolated antibody or antigen binding portion thereof of  claim 1 , wherein the V H  antibody chain comprises the sequence identified by SEQ ID NO: 23 and wherein the V L  antibody chain comprises the sequence identified by SEQ ID NO: 37 or SEQ ID NO: 38. 
     
     
         4 . The isolated antibody or antigen binding portion thereof of  claim 1 , wherein the V H  antibody chain comprises the sequence identified by SEQ ID NO: 24 and wherein the V L  antibody chain comprises the sequence identified by SEQ ID NO: 37 or SEQ ID NO: 38. 
     
     
         5 . A nucleic acid encoding the isolated antibody or antigen binding portion thereof of  claim 1 . 
     
     
         6 . A vector comprising a nucleic acid according to  claim 5 . 
     
     
         7 . A host cell comprising a nucleic acid according to  claim 5 . 
     
     
         8 . A method for the production of an isolated antibody or antigen binding portion thereof, said method comprising culturing of a host cell of  claim 7  under conditions allowing the expression of the antibody or binding portion thereof and recovering the antibody or binding portion thereof from the culture. 
     
     
         9 . A pharmaceutical composition comprising an isolated antibody or antigen binding portion thereof of  claim 1 .